Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005664809
Mon, 21.07.2025
Evotec SE
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec’s differentiated platforms
High-margin technology license revenues expected to have a stronger impact than anticipated
Significant cost optimization in excess of initial targets from Priority Reset [ … ]
Wed, 25.06.2025
Evotec SE
NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury (“AKI”) patients, developed as part of a research consortium led by Kidney Research UK
The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chr [ … ]
Tue, 03.06.2025
Evotec SE
All agenda items adopted
Under the topic “Pioneering Drug Discovery” CEO Dr Christian Wojczewski presented Evotec’s current situation and strategic outlook
46.45% of the registered share capital represented
Hamburg, Germany, 03 June 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that [ … ]
Wed, 07.05.2025
Evotec SE
Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.
The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies.
[ … ]
Tue, 06.05.2025
Evotec SE
Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just – Evotec Biologics with continuing growth momentum
Strong progress in strategic protein degradation partnership with Bristol Myers Squibb
Strategy building on technology and science leadership: Focus on high-growth, high-value segme [ … ]
Tue, 29.04.2025
Evotec SE
Hamburg, Germany, 29 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call [ … ]
Thu, 24.04.2025
Evotec SE
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs
Performance-based and program-based payments of in total US$ 75 m to Evotec
Hamburg, Germany, 24 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced furt [ … ]
Thu, 17.04.2025
Evotec SE
Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth
Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence
Strong Q4 2024 revenue and EBITDA results in spite of ch [ … ]
Thu, 10.04.2025
Evotec SE
Hamburg, Germany, 10 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025.
The Company is going to host a conference call to discuss 2024 results as well as to provide an update on the concluded strategic review process. The confe [ … ]
Tue, 04.03.2025
Evotec SE
Ongoing strategic partnership advances joint pipeline in neurodegeneration research
Evotec receives a $20 million payment to further progress research
Hamburg, Germany, 04 March 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced another major accomplishment in its long [ … ]
